#United States #Sacramento #CBD #Pico IV #Liquivida

PICO IV Announces Partnership with Liquivida

PICO IV, a leader in innovative health solutions, has made headlines by announcing a strategic partnership with Liquivida, a prominent name in the wellness and IV therapy sectors. This collaboration aims to merge expertise in IV hydration with the cutting-edge science of CBD, pioneering new pathways for health and wellness.

At the core of this partnership is Liquivida's founder, Sam Tejada. Recognized for his leadership and contributions to holistic health, Tejada has joined the PICO IV Advisory Board, also taking on the role of spokesperson for the brand. His involvement highlights a commitment to raising awareness about the clinical applications of CBD and educating individuals about the endocannabinoid system (ECS), which is integral to maintaining bodily balance and regulation.

"This isn't just about introducing a new product; it signifies the dawn of a transformative category in treatment," Tejada stated. He emphasized that Liquivida's stringent selection process ensures only the safest, scientifically-backed solutions enter their clinics.

For those unfamiliar, the ECS plays a vital role in various physiological processes, yet it remains under-discussed in mainstream medical education. As such, the partnership's emphasis on the ECS comes at a critical juncture. It aims to equip healthcare providers and patients with knowledge necessary for integrated CBD healthcare solutions.

Unlike traditional oral and topical CBD products, which have gained traction since the Farm Bill of 2018, PICO IV utilizes a groundbreaking approach. The company boasts a patent-pending technology that minimizes CBD particle size to the pico level, significantly enhancing absorption rates and bioavailability. This innovative process facilitates the development of a sterile CBD solution, the first of its kind in the world, elevating both safety and efficacy in cannabinoid delivery systems.

The CBD solution from PICO IV is manufactured within a rigorous cGMP facility. Each batch undergoes strict testing and is sterilized through advanced e-beam technology—a method celebrated for eliminating contaminants while preserving product quality.

Joe Young, CEO of PICO IV, expressed enthusiasm about the trajectory of the newly launched sterile CBD solution. He highlighted the critical importance of trust and safety throughout the manufacturing process. “Given that our sterile CBD is a new innovation in the market, we’re aware of the tremendous potential ahead of us. Our foremost priority has always been ensuring safety at every manufacturing stage,” he stated.

This partnership aims not only to create exciting joint ventures but also to educate the medical community about the ECS. As the understanding of this crucial system evolves, so too will the integration of CBD into clinical settings. Liquivida is poised to play an instrumental role in this educational mission, working with a network of affiliate doctors to communicate the science behind sterile CBD and its role within advanced wellness protocols.

At a time when the trend towards holistic and evidence-based healthcare continues to rise, the partnership between PICO IV and Liquivida represents an essential step forward. By bridging the gap between natural treatments and scientifically validated methods, these two companies are setting a new standard for wellness solutions that can have a lasting impact on patient health.

In summary, PICO IV and Liquivida’s collaboration is expected to redefine the landscape of therapeutic options available to patients. By combining innovative science with a dedicated approach to wellness, the ambitions of this partnership can yield a healthier future for all.

For more information on this exciting partnership, visit PICO IV and Liquivida.